Clinical trial · Observational
Cancer-Associated Muscle Atrophy and Weakness: An Investigation of Etiology
NCT03012139CI-TRIAL-00042886completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is designed to gain a better understanding of the mechanisms leading to muscle wasting and metabolic abnormalities in skeletal muscle of cancer patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cachexia; Cancer | — | UNRESOLVED | — |
| Metastatic Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- Cancer with cachexia
- description
- Men and women (ages 35-80 years) with cancer cachexia (≥5% drop in body mass in less than 12 months)
- label
- Cancer without cachexia
- description
- Men and women (ages 35-80 years) with cancer but without cachexia of similar age and sex as the group with cachexia
- label
- No cancer
- description
- Men and women (ages 35-80 years) without cancer, but similar age and sex as groups with cancer.
Primary outcomes (2)
- measure
- Skeletal muscle oxidative capacity
- timeFrame
- Approximately within a month of recruitment
- description
- Muscle oxidative capacity will be measured by magnetic resonance spectroscopy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 35 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Age 35-80 years * Diagnosis of metastatic cancer with cachexia (≥5% drop in body mass in less than 12 months), metastatic cancer without cachexia (\<5% drop in body mass in 12 months) or no history of cancer but similar in age and sex as other groups. Exclusion Criteria: * Current use of vitamin D analogs * Fasting plasma glucose ≥126 mg/dL * Renal failure (serum creatinine \> 1.5mg/dl) * Chronic active liver disease (Bilirubin \> 17mmol/L, AST\>144IU/L, or ALT\>165IU/L) * Contraindications to MRI (e.g., pacemaker, ferrous materials within body). * Active coronary artery disease or history of unstable macrovascular disease (unstable angina, myocardial infarction, stroke, and revascularization of coronary, peripheral or carotid artery within 3 months of recruitment) * Renal insufficiency/failure (serum creatinine \> 1.5mg/dl) * Oral warfarin group medications or history of blood clotting disorders. * People who have taken Bevacizumab * Platelet count \<100,000 per uL * Pregnancy or breastfeeding * Alcohol consumption greater than 2 glasses/day or other substance abuse * Untreated or uncontrolled thyroid disorders * Debilitating chronic disease (at the discretion of the investigators) * Previous injury/trauma/surgery to the region being measured without full recovery * Pain in the area to be assessed * Any medical condition affecting the ability to execute a maximal muscle contraction * The presence of infections, highly communicable diseases (AIDS, active tuberculosis, veneral disease, hepatitis) or metastatic bone disease that may interfere with safely executing maximal effort. * Significant neurological or musculoskeletal disorders or disease that may interfere with safely executing maximal contraction * Any congenital, developmental, or other bone disease or previous surgeries that may interfere with successful testing
References
Publications (0)
Data not yet available
No reference posted for this study.